Kevin Mulvey, MD
Hematology & Oncology · Post Falls, IDNPI 1215015490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $193 and has fallen 89.7% since, to $20 in 2023. That places this record below the midpoint for hematology & oncology clinicians in ID, where the typical reported total is $2,538.
Across 23 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$95
- Sun Pharmaceutical Industries Inc.$40
- E.r. Squibb & Sons, L.L.C.$38
- Johnson & Johnson$35
- Amgen$28
- Sanofi$27
- plus $220 from 12 others
Across 13 payments — averaging $465.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
- Incyte Corporation$2K
- Pfizer$1K
What the payments were for
- Food & beverage$43991%
- Education$449%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 2 | $95 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Johnson & Johnson | 2 | $35 |
| Amgen | 1 | $28 |
| Sanofi | 1 | $27 |
| AstraZeneca | 1 | $24 |
| Seagen Inc. | 1 | $24 |
| Gilead | 2 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| GSK | 1 | $17 |
| Exelixis Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Novartis | 1 | $16 |
| Pfizer | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $12 |
How this compares
$483 in reported general payments places this provider in the 20th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 17 | $308 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Post Falls
- Danko MartincicPost Falls$1.1M
- Jeffrey AllenPost Falls$3K
- Bobby ChawlaCaldwell$1M
- Christian ShullIdaho Falls$150K
- Dane DicksonRexburg$21K
- Ian QureshiNampa$18K
- Nathan AdamsIdaho Falls$16K
- Andrew KominskyCoeur D Alene$13K
- David BartelsCoeur D Alene$11K
- Maria Cervantes FullmerIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.